Search Results

You are looking at 71 - 80 of 131 items for :

  • "symptom burden" x
  • Refine by Access: All x
Clear All
Full access

Patterns of Palliative Care Consultation Among Elderly Patients With Cancer

Eric J. Roeland, Daniel P. Triplett, Rayna K. Matsuno, Isabel J. Boero, Lindsay Hwang, Heidi N. Yeung, Loren Mell, and James D. Murphy

combined integration of palliative care with standard oncology care for any patient with metastatic cancer or high symptom burden. 10 Survey studies have found an increase in the availability of palliative care across the United States, 1 with a near 3

Full access

Practice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post–JAK2 V617F Discovery Era

Elizabeth M. Kander, Alison R. Moliterno, Alfred Rademaker, Michael B. Streiff, Jerry L. Spivak, and Brady L. Stein

it had the potential to cure PV. This Figure 4. Target platelet count in polycythemia vera. perception is in keeping with clinical data regarding improvement in symptom burden. In the more than 10 years since the prior survey

Full access

Value Tools for Patients in Cancer Care

Katy Winckworth-Prejsnar, Lisa Korin Lentz, Elizabeth A. Nardi, Sandhya Pruthi, C. Lyn Fitzgerald, and Robert W. Carlson

. Zafar Y Goetzinger AM Fowler R . Impact of out-of-pocket expenses on cancer care [abstract] . J Clin Oncol 2011 ; 29 ( Suppl ): Abstract 6006 . 8. Lathan C Cronin A Tucker-Seeley R . Association of financial strain with symptom burden and

Full access

By the Pricking of My Thumbs, Something Wicked This Way Comes: Sporadic Cancers Versus Eponymous Hereditary Cancer Predisposition Syndromes

Christos Vaklavas, John R. Ross, Lisle M. Nabell, Andres Forero, Martin J. Heslin, and Tina E. Wood

developed later, a striking contradiction was noted between the extent of disease and the patient's minimal symptom burden. Physical examination was negative for abnormal findings. A thorough family history was unrevealing. She had one brother, who was

Full access

Barriers and Approaches to the Successful Integration of Palliative Care and Oncology Practice

Jamie H. Von Roenn, Raymond Voltz, and Alain Serrie

any patient with metastatic cancer and/or high symptom burden. 3 The Associazione Italiana di Oncologia Medica has stated that “taking care of patients with cancer means not only to offer them the best therapeutic options but also to understand and

Full access

Palliative Radiotherapy Versus Esophageal Stent Placement in the Management of Patients With Metastatic Esophageal Cancer

Emily J. Martin, Andrew R. Bruggeman, Vinit V. Nalawade, Reith R. Sarkar, Edmund M. Qiao, Brent S. Rose, and James D. Murphy

Background Most patients with esophageal cancer are found to have locally advanced or metastatic disease at the time of initial diagnosis. 1 – 4 Such advanced disease is associated with significant symptom burden and corresponding decrease in

Full access

Durable Response to PD-1 Blockade in a Patient With Metastatic Pancreatic Undifferentiated Carcinoma With Osteoclast-Like Giant Cells

Robert J. Besaw, Adrienne R. Terra, Grace L. Malvar, Tobias R. Chapman, Lauren M. Hertan, and Benjamin L. Schlechter

compression and pain, reducing the patient’s ability to eat. She was referred for palliative RT to mitigate her symptom burden due to mass effect. Given limited data regarding the efficacy of RT in UCOGC histology, but due to the presence of spindle cell

Full access

Clinical Impact of Local Progression in Pancreatic Cancer

Nicholas Cardillo, Daniel M. Seible, Katherine E. Fero, Andrew R. Bruggeman, Reith R. Sarkar, Alexa Azuara, Daniel R. Simpson, and James D. Murphy

cancer at a single academic institution from 2004 through 2015 were retrospectively reviewed. Available medical records, pathology, and radiology reports were reviewed in entirety, with a focus on defining the symptom burden that patients experience with

Full access

Addressing Survivorship in Cancer Care

James McCanney, Katy Winckworth-Prejsnar, Alyssa A. Schatz, Elizabeth A. Nardi, Andrea J. Dwyer, Christopher Lieu, Yelak Biru, and Robert W. Carlson

focused on QoL, symptom burden, and economic implications of treatment, among other outcomes. Emphasis is given to ensure the medical community's focus is not on cure at any cost. Providers must better understand QoL after treatment, patient values

Full access

NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non–Small Cell Lung Cancer

Matthew A. Gubens and Marianne Davies

high PD-L1 expression (ie, those with a high disease or symptom burden), with KEYNOTE-189 showing improved OS compared with chemotherapy alone. 4 Although this regimen carries greater toxicity than pembrolizumab alone, clinicians and patients may